CA-SAMBANOVA-SYSTEMS
26.10.2021 15:02:06 CEST | Business Wire | Press release
SambaNova Systems , the company building the industry’s most advanced software, hardware and services to run AI applications, today announced that its AI membership program for the enterprise, ELEVAITE , is now open for applications. The program is designed to lead select cohorts of enterprises into the AI-enabled future leveraging SambaNova’s unmatched AI technology, solutions, expertise, and proven success while addressing the biggest challenges of starting and scaling an AI program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026005330/en/
“The emergence of AI and its expected impact on the Global 2000 – akin to the impact of the internet – is upon us,” said Rodrigo Liang, co-founder and CEO of SambaNova. “For those with a desire to embrace the transformational power of AI, there are huge opportunities. With SambaNova ELEVAITE, enterprises will receive unmatched education and technical guidance that directly supports successful AI initiatives from conception to deployment, scalability, and ROI with market visibility for their technology leadership.”
Leaders across industries such as financial services, energy, manufacturing, healthcare, and more realize it is time to apply AI to their organization’s data resources. ELEVAITE is uniquely designed to accelerate selected cohort enterprises’ deployment of the most advanced and performant AI software, hardware, and services available for AI, machine learning, and deep learning.
As an ELEVAITE member, SambaNova teams will work with businesses to determine the most impactful AI technologies based on SambaNova’s experience and deep understanding of enterprise needs to deliver business impact. These include use cases for Natural Language Processing, Vision, and Recommendation.
“Enterprises well suited to participate in ELEVAITE are those that recognize the imperative to drive focus on new initiatives when looking to accelerate AI capabilities inside organizations,” said Marshall Choy, VP of Product at SambaNova. “Working together, ELEVAITE members and SambaNova will accelerate the deployment and scalability inside their enterprises.”
“ELEVAITE membership is designed to deliver unmatched education and awareness on a personal and cohort basis to accelerate enterprises’ transformation to an AI-Enabled organization,” said Amy Love, Chief Marketing Officer at SambaNova. “The program also furthers the market-leading standing of the selected companies by presenting them as leaders in their field.”
ELEVAITE members receive access to three categories of benefits:
- Unmatched Collaboration for Success: By providing customized scoping, implementation and scaling of AI solutions, SambaNova’s dedicated technical and account leads will be with you every step of the way.
- Institutionalized Skills and Knowledge : SambaNova founders, senior executives, board members, technologists, and industry luminaries will educate participating organizations to deliver the resources required to implement AI initiatives and develop new AI skills.
- ELEVAITED Visibility Driving Enterprise Value: With access to the SambaNova VisionAIres program, participants can increase the visibility of their AI initiatives, develop thought leadership and enhance their company’s reputation through media exposure.
ELEVAITE reduces the risk for enterprises and commits to scalable deployment by providing access to unique SambaNova resources and knowledge to ensure they are successful with AI. Members have access to SambaNova’s turnkey platform, including Dataflow-as-a-Service™, an extensible AI services platform, and DataScale®, an integrated software and hardware platform delivering unrivaled performance, accuracy, scale and ease of use built on SambaNova’s Systems Reconfigurable Dataflow Architecture™. This eliminates the need for massive data science staffing, significantly reducing the cost of investment.
To learn more, schedule an executive conversation or to apply for the program, visit sambanova.ai/elevaite . The selection process will occur this fall and the first cohort program will begin in January 2022.
About SambaNova Systems:
SambaNova Systems is an AI innovation company that empowers organizations to deploy best-in-class solutions for natural language processing, computer vision, recommendation systems, and AI for science with confidence. SambaNova's flagship offering, Dataflow-as-a-Service™, helps organizations rapidly deploy AI in days, unlocking new revenue and boosting operational efficiency. SambaNova's DataScale® is an integrated software and hardware system using Reconfigurable Dataflow Architecture™, along with open standards and user interfaces. Headquartered in Palo Alto, California, SambaNova Systems was founded in 2017 by industry luminaries and hardware and software design experts from Sun/Oracle and Stanford University. Investors include SoftBank Vision Fund 2, funds and accounts managed by BlackRock, Intel Capital, GV, Walden International, Temasek, GIC, Redline Capital, Atlantic Bridge Ventures, Celesta, and several others. For more information, please visit us at sambanova.ai or contact us at info@sambanova.ai . Follow SambaNova Systems on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005330/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom